Authentic voices. Remarkable stories. AOL On Originals showcase the passions that make the world a more interesting place.
In a compelling series of verite encounters, Win Win provides unique access into the minds and lives of the world’s most-celebrated entrepreneurs and athletes.
Explore what it means to be human as we rush head first into the future through the eyes, creativity, and mind of Tiffany Shlain, acclaimed filmmaker and speaker, founder of The Webby Awards, mother, constant pusher of boundaries and one of Newsweek’s “women shaping the 21st Century.”
Nicole Richie brings her unfiltered sense of humor and unique perspective to life in a new series based on her irreverent twitter feed. The show follows the outspoken celebrity as she shares her perspective on style, parenting, relationships and her journey to adulthood.
Comedy is hard, but teaching comedy to children is hilariously difficult. Kevin Nealon is giving the challenge to some world-famous comedians. As these young minds meet with comedy’s best, get ready to learn some valuable comedy lessons, and to laugh!
James Franco loves movies. He loves watching them, acting in them, directing them, and even writing them. And now, he’s going to take some of his favorite movie scenes from the most famous films of all time, and re-imagine them in ways that only James can.
The story of punk rock singer Laura Jane Grace of Against Me! who came out as a woman in 2012, and other members of the trans community whose experiences are woefully underrepresented and misunderstood in the media.
Executive produced by Zoe Saldana (who will be the subject of one episode), a celebrity travels back to their hometown to pay tribute to the one person from their past (before they were famous) who helped change their life by giving them an over-the-top, heart-felt surprise.
Enter the graceful but competitive world of ballet through the eyes of executive producer, Sarah Jessica Parker. This behind-the-scenes docudrama reveals what it takes to perform on the ultimate stage, the New York City Ballet. Catch NYCB on stage at Lincoln Center.
Park Bench is a new kind of "talking show" straight from the mind of born and bred New Yorker and host, Steve Buscemi.
Go behind the scenes with some of the biggest digital celebrities to see what life is like when the blogging and tweeting stops.
Digital influencer Justine Ezarik (iJustine) is back. After covering the world of wearable tech last season, iJustine is expanding her coverage this year by profiling the hottest tech trends across the country.
Documentary shorts conceived of and directed by famous actors. Jeff Garlin, Katie Holmes, Alia Shawkat, Judy Greer, and James Purefoy
A 12 episode documentary series following 5 startup companies competing in the 2013 San Francisco TechCrunch Disrupt Startup Battlefield as they fine tune their products and eventually present in front of a panel of judges in hopes of winning $50,000 in funding.
Morningstar markets editor Jeremy Glaser takes the temperature of several firms on the hot seat.
Tags:5 Firms That Try to Beat the Heat,bp oil,firm investigations,goldman sachs,investing in mutual funds,investment advice,investment options,Investment tips,jason stipp,jeremy glaser,morningstar
Grab video code:
5 Firms That Try to Beat the Heat
Jason Stipp: I’m Jason Stipp with Morningstar and welcome to the Friday Five. As it starts to warm up outside, lots of folks are going out and feeling the heat, but some folks in Corporate America are really feeling the heat.
Here with me to talk about who is trying to beat the heat is Morningstar markets editor, Jeremy Glaser. Jeremy thanks for joining us.
Jeremy Glaser: You are welcome, Jason.
Jason Stipp: So, what do you got for the Friday Five this week?
Jeremy Glaser: Well, this week we’ll see even more heat being put on BP, Goldman Sachs and the rest of the big banks. CVS is finding itself in a little bit of a pickle. And finally, the regulators are turning their eye towards Apple and putting the heat on there.
Jason Stipp: Well, it’s no surprise that BP is continuing to feel the heat, but it really got cranked up this week. What have you seen there?
Jeremy Glaser: That’s absolutely right, Jason. BP has been under pressure for quite a few weeks now. But even as they finally have been able to contain some of the oil that’s spilling into the Gulf, the rhetoric is actually stepping up in Washington. There is now talk that it’s unconscionable for BP to continue to pay its dividend, that they are going to have to have essentially unlimited liability for the entire Gulf spill including lost wages for the people who are on offshore platforms or for fisherman who aren’t going to be able to do their job because of the oil spill.
I think that the costs were pretty uncertain before and I think that uncertainty just continues to grow, even as less oil is being spilled into the Gulf every day.
Jason Stipp: There’s talk this could extend into August as they are still drilling the relief well. So, certainly the heat is going to continue probably all through summer.
Another one that’s been on the hot seat recently was Goldman Sachs. I know that they were in Washington and really got grilled by some Congressmen, but they also were still continuing to feel the heat this week. What did you see on Goldman?
Jeremy Glaser: Goldman Sachs received a subpoena for even more documents related to transactions that they completed in the years leading up to the financial crisis. They have provided Congress with a lot of documents before, millions of documents. But apparently a lot of them were unrelated to the transactions and it was very difficult for anyone to be able to comb through it and figure out what was pertinent and what wasn’t.
It almost seems like Goldman is trying to intentionally make it difficult for people to figure out exactly what happened. When you listen to the testimony that they had before in front of Congress and then with some of the document dumps that they’ve been doing. It seems like they are trying to hide something or at least make it difficult for investigators to do their job. I think that they’re going to have to change their tune pretty quickly or they’re got to find that a lot more of these allegations are coming. The government will continue to turn the heat up throughout the rest of the year.
Jason Stipp: Speaking of the banks and derivatives obviously another big issue that the banks have been on the hot seat for before. Some news on that front this week, what did you see?
Jeremy Glaser: It’s certainly possible that the derivatives amendments of the financial reform bill got a big boost this week as Blanche Lincoln won the Democratic runoff for the Senate seat in Arkansas. She has been one of the biggest proponents of an amendment to the bill that would force the big banks to take the derivatives trading operations which are hugely profitable for them, and spin them off into separate entities.
She is very upset that they get to use FDIC-insured deposits to make these big derivative bets which could have led to a lot of the volatility we saw during the financial crisis. So, if she is back in the Senate or at least is going to be running on this for the general election, she is going to be pushing really hard, and it could mean that there is a better chance that this amendment will get into the final bill.
Jason Stipp: The interesting election for the banks to watch. Going on now to the retail area and the pharmacies, there’s some interesting questions about CVS and Caremark, a company that they bought a while ago that’s creating a little bit of heat potentially for the company also involving Walgreens. It’s kind of a complicated story. Can you entangle that a little bit for us?
Jeremy Glaser: When CVS bought Caremark, there was a lot of talk about there being a potential conflict of interest. Now what Caremark essentially does is they are a third-party administrator of a prescription drug benefit through any number of health plans. And there was a lot of talk about if Caremark was going to unnecessarily favor people to go to CVS Pharmacy to get their drugs versus, say, Walgreens.
Now people thought it would be years before any of this came to a head, but Walgreens kind of abruptly said this week that no new members into the Caremark network could be able to pick up their prescriptions at Walgreens. Now this is a big care to Caremark because people like the option to be able to go to Walgreens. So they retorted by saying that no Caremark members will be able to go to Walgreens in the future.
So this seems to be a lot of corporate back and forth and no one knows what’s really going to end. But our analyst thinks that if other members of the Caremark network follow Walgreens' lead and start restricting the ability of members to actually get their drugs quickly, it could lead to the breakup of CVS and Caremark, and this conflict of interest could be too big to overcome. So it’ll be definitely interesting to watch to see how this plays out and to see where people are going to be getting their drugs from in the future.
Jason Stipp: So lastly, for number five, Apple was in the news this week because of the launch of the new iPhone that they have on there. But you also said they might be feeling a little bit of heat in other area. Tell us a little bit about what you see on the Apple front.
Jeremy Glaser: Along with the iPhone, Apple also announced that iAds are going to be rolling out very soon. Now these ads are meant to compete against primarily Google in the ads that are served up to keep a lot of apps free.
Now Apple wants to get a big slice of this market which makes sense because it could potentially be a very lucrative one and they don’t want to cede it to Google, but it seems like they are starting to take steps to make it more and more difficult for people to use anything but the Apple ad service.
They’re going to block third-party tracking software to see who is necessarily looking at the ads, unless it comes from completely independent publishers. And other moves are starting to raise the eyebrows of some regulators. They’re worried that Apple is going to take a monopoly over this platform and there’s obviously nothing formal announced yet, and it could be years before anything comes of it. But it’s definitely a shot across the bow that Apple really needs to be careful about some of these antitrust issues.
Jason Stipp: So maybe if the regulatory heat comes down, we’ll see if Steve Jobs has short sleeve versions of his trademark black turtleneck.
Jeremy thanks for joining me.
Jeremy Glaser: You’re very welcome, Jason.
Jason Stipp: For Morningstar, I am Jason Stipp. Thanks for watching.